Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind active-controlled study of oral BG2109 during controlled ovarian hyperstimulation in women undergoing ART
CTR20222174Phase 2Terminated
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of linzagolix in infertility (2 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Rate of suppression of premature LH surge from start of study treatment to hCG injection date. Started Sep 2022; status: terminated.
02
Drugs
linzagolix
03
Conditions
infertility
Beyond the preview
Go deeper on CTR20222174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222174.